Drug Type Fusion protein |
Synonyms |
Target |
Mechanism IL-15Rα agonists(Interleukin-15 receptor subunit alpha agonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 1 | US | 10 Aug 2022 | |
Solid tumor | Phase 1 | US | 10 Aug 2022 |